Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Varicella Vaccine · 2 trials · 3 indications
The seroresponse rate of VZV antibodies on Day 42 after vaccination among susceptible population.
| Arm | Type | Description |
|---|---|---|
| No vaccination history group | EXPERIMENTAL | Participants aged 1-12 years with no vaccination history of varicella-containing vaccine |
| Vaccination history group | EXPERIMENTAL | Participants aged 2-12 years have received 1 dose of varicella vaccine |
| Varicella vaccine group | EXPERIMENTAL | Participants will receive a single dose of investigational varicella vaccine on Day 0. |
| Varivax | ACTIVE_COMPARATOR | Participants will receive a single dose of Varivax on Day 0. |
| Name | Type | Description |
|---|---|---|
| Varicella Vaccine | BIOLOGICAL | Varicella vaccine manufactured by Sinovac |
| Varivax | BIOLOGICAL | lyophilized powder,subcutaneous injection |
Inclusion Criteria: 1. Healthy children aged 1-12 years; 2. Vaccination history: * Participants aged 1 year old: no vaccination history with any varicella containing vaccine; * Participants aged 2\~12 years old: no vaccination history with any varicella containing vaccine, or have received 1...
The varicella vaccine is used to prevent varicella, commonly known as chickenpox. Sinovac Biotech is developing this live vaccine for use in healthy children, with clinical studies conducted in Vietnam and the Philippines. It is intended for immunization against the varicella virus in pediatric populations.
Sinovac Biotech, Ltd is developing the varicella vaccine. The company trades under the ticker SVA. Sinovac is running Phase 3 clinical trials of the live varicella vaccine in healthy children in Vietnam and the Philippines.
The varicella vaccine is in Phase 3 clinical development. It is an investigational vaccine and is not approved. Two Phase 3 trials have been conducted, one completed in the Philippines and one not yet recruiting in Vietnam, with a combined enrollment of 942 participants.
The varicella vaccine has been studied in two Phase 3 trials. NCT06314724 evaluated immunogenicity and safety in healthy children aged 12 to 15 months in the Philippines and is completed with 642 participants. NCT07473427 is a Phase 3 trial in healthy Vietnamese children with 300 planned participants and has not yet started recruiting.
The varicella vaccine is a live vaccine designed to induce an immune response against the varicella virus, providing protection against chickenpox. Both Phase 3 trials assessed immunogenicity and safety in healthy children, with the trials being randomized, double-blind, and active-controlled.
The varicella vaccine from Sinovac Biotech is investigational and remains in Phase 3 clinical development. It has not been approved. The two Phase 3 trials, NCT06314724 in the Philippines and NCT07473427 in Vietnam, evaluated the vaccine in healthy children.